FDA approves combination therapy Juvisync

FDA approves combination therapy Juvisync

First combination drug to treat type 2 diabetes and high cholesterol in one tablet

The U.S. Food and Drug Administration today approved Juvisync (sitagliptin and simvastatin), a fixed-dose combination (FDC) prescription medication that contains two previously approved medicines in one tablet for use in adults who need both sitagliptin and simvastatin.

(More)